How oxidation controls key protein switches in cells
Official title: Complexity of Protein Tyrosine Phosphatase Oxidation
Funded at State University of New York at Albany · NIH-11324569 · Data updated 2026-11-12
Researchers are looking at how small oxidation changes switch off protein regulators in cells, which could help people with diseases linked to oxidative stress.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Albany NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | June 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $375,753 |
| NIH project number | 5R35GM153449-03 |
| Project ID | NIH-11324569 on NIH RePORTER |
Who could benefit from this research
✓Could help
Although this is primarily lab-based and not enrolling patients now, people with conditions tied to oxidative stress or dysregulated cell signaling (for example certain cancers, neurodegenerative, or heart diseases) would be the kinds of patients who might benefit from future treatments arising from this work.
✕Less likely to help
Patients with conditions that do not involve oxidative signaling pathways or where disease mechanisms are purely structural or non-redox related are unlikely to benefit directly from this project.
What this research studies
This lab project will map how protein tyrosine phosphatases (important regulators of cell signaling) are reversibly turned off by oxidation using biochemical tools and cellular models. The team will identify new oxidation and reduction mechanisms they recently discovered and test how these changes alter cell signaling and function. Work will include experiments in cultured cells and in vivo models to track oxidation states, manipulate specific proteins, and observe downstream effects. The aim is to find molecular targets that could guide future therapies for conditions driven by disrupted redox signaling.
Why it matters
Potential benefit: If successful, this work could point to new ways to restore proper cell signaling and lead to therapies for diseases linked to oxidative stress, such as some cancers, neurodegenerative, and cardiovascular conditions.
How similar studies have gone: Previous research has shown that oxidation of protein tyrosine phosphatases affects cell signaling and disease, but the specific oxidation-relay mechanisms proposed here are recently described and remain to be validated.
Where this research is happening
-
State University of New York at Albany
Albany, United States Active
Researchers
- Principal investigator: Boivin, Benoit — State University of New York at Albany
- Study coordinator: Boivin, Benoit
Related research
Other NIH-funded projects on the same topics.
-
Cross-disease small molecule therapy for CAG expansion spinocerebellar ataxias
A new NIH grant is exploring whether existing and natural small molecules can lower harmful CAG RNA and proteins across several spinocerebellar ataxias to help people with these conditions.
-
New small molecule therapeutics to help myotonic dystrophy
A new NIH-funded project tests specially designed small molecules to lower harmful RNA activity in myotonic dystrophy and related diseases, aiming to reduce disease-driving RNA effects.
-
Biofilm structure and its role in the start of gum disease
A researchers team will study how tiny communities of bacteria at the gumline interact with the mouth’s tissues to spark inflammation that leads from healthy gums to periodontal disease.
-
Understanding how unusual RNA translation happens in neurological diseases
Researchers are studying how RNAs can start making proteins in unexpected ways in neurodegenerative diseases, which could reveal new targets for therapy.
-
Early-life neighborhood redlining and lifetime mortality in a historical cohort
This project looks at whether growing up in areas graded or disinvested by HOLC in the 1930s affects mortality later in life for people born in 1930–1940.
-
Activating PTP1B and Other Phosphatases with Small Molecules
A safety-focused, patient-friendly look at a project that aims to turn on natural enzymes in our cells to help correct harmful signals in diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.